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Abstract
Purpose Delayed chemotherapy-induced nausea and
vomiting (CINV) remains an important adverse effect of mod-
erately emetogenic chemotherapy not containing
anthracyclines and cyclophosphamide (non-ACMEC). In this
review, we summarize current literature to update recommen-
dations for delayed CINV prophylaxis after non-AC MEC.
Methods We conducted a systematic search in PubMed and
conference proceedings from ASCO, ESMO, and MASCC.
Included randomized controlled trials (RCTs) aimed to pro-
spectively evaluate the efficacy of two or more antiemetic
strategies in the prevention of delayed CINVafter the admin-
istration of non-AC MEC. At least one of the following end-
points was used: complete response, complete control, no
nausea, no vomiting, and/or no use of rescue medication.
Results Our search provided 247 publications. Nine met the
predefined criteria. Included RCTs reported outcomes on
palonosetron, aprepitant, casopitant, netupitant/palonosetron
(NEPA), olanzapine, and megestrol acetate.
Conclusions Superiority of palonosetron over first-generation
5-HT3 receptor antagonists for the prevention of acute and
delayed CINV after non-AC MEC has not been proven. The
addition of an NK1 receptor antagonist to first-generation 5-
HT3 receptor antagonists does not significantly improve the
incidence of delayed CINV after non-AC MEC. The efficacy
of a single-day regimen of dexamethasone with palonosetron
is non-inferior to multiday dexamethasone. NEPA,
olanzapine, and megestrol acetate show highly effective com-
plete response (CR) rates.
Keywords Antiemetics . Delayed CINV .Moderately
emetogenic chemotherapy
Introduction
Delayed chemotherapy-induced nausea and vomiting
(CINV), defined as nausea and vomiting occurring more than
24 h after completion of chemotherapy, remains an important
and common adverse event complicating cancer treatment.
Delayed CINV significantly interferes with patient’s quality
of life (QOL) and daily functioning [1, 2]. Incidence and se-
verity of CINV are affected by patient- and treatment-related
factors. Characteristics associated with a higher risk include
female sex, anxiety, and poor control with previous chemo-
therapy [3, 4]. Delayed CINV is influenced by the effective-
ness of control of the acute phase of CINV, as well as the
intrinsic emetogenicity of the drug. The risk of delayed CINV
has been studied best in chemotherapy regimens containing
high-dose cisplatin or anthracyclines and cyclophosphamide
(AC) combinations. However, delayed CINV is also associat-
ed with moderately emetogenic chemotherapy (non-AC
MEC) regimens [5–10]. Non-AC MEC consists of a broad
range of chemotherapeutic agents, with emetogenic potentials
of 30 to 90 %; agents like oxaliplatin and irinotecan have an
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emetogenic potential in the lower part of this range, as op-
posed to carboplatin, which is at the high end [11, 12].
In 2013, the Multinational Association for Supportive
Care in Cancer (MASCC) and the European Society of
Medical Oncology (ESMO) last updated their guidelines
for the management of CINV in adults [13]. In 2011,
the American Society of Clinical Oncology (ASCO)
published the last updated clinical practice guideline
for antiemetics in oncology [14]. All guidelines recom-
mend palonosetron combined with dexamethasone for
the prevention of acute CINV following non-AC MEC,
with multiday oral dexamethasone as the preferred treat-
ment for the prevention of delayed CINV (level of ev-
idence IIb). These recommendations are based however
on phase III trials, which did not evaluate the combina-
tion of palonosetron and dexamethasone in MEC, but
only in highly emetogenic chemotherapy (HEC) and
AC chemotherapy [15, 16]. Also, patients in the afore-
mentioned trials did not receive optimal antiemetic treat-
ment with NK1 receptor antagonists, as recommended
for HEC and AC chemotherapy, which may have influ-
enced the results.
Despite the recommended combination of palonosetron
and multiday dexamethasone, many patients still experience
delayed CINV following non-AC MEC. In a small observa-
tional trial with colorectal cancer patients, palonosetron and
dexamethasone failed to provide both complete response (CR)
and complete control (CC) in 15 % of the patients in the
delayed phase [17]. In another phase III trial with
palonosetron and dexamethasone administered for 3 days, al-
most 25 % of the patients did not achieve CR in the delayed
phase [18]. Further evidence on the efficacy of new strategies
to prevent delayed CINV after non-AC MEC is therefore
needed. This systematic review aims to provide a comprehen-
sive assessment of recently performed randomized controlled
trials (RCTs) on this specific topic.
Methods
Search strategy
We conducted a systematic search in PubMed and conference
proceedings of ASCO, ESMO, and MASCC in August 2014.
For PubMed, the following syntax was applied: “chemother-
apy-induced nausea and vomiting [tiab]” OR “CINV [tiab]”
OR “emesis [tiab]” OR “delayed nausea [tiab]” OR “moder-
ately emetogenic [tiab]” OR “MEC [tiab]”, with limits: clini-
cal trial, full text, English, humans, adult, and date from Jan-
uary 1st 2009 to July 31st 2014. An electronic search was
undertaken of conference proceedings of ASCO, ESMO,
and MASCC from January 1st 2009 to July 31st 2014.
Selection criteria
Potentially relevant studies retrieved by the PubMed and con-
ference proceedings searches were independently reviewed
for eligibility by two investigators (M.V.D.V. and E.C.W.N.).
Any disagreement between the reviewers was resolved by re-
examination and subsequent discussion to reach a consensus.
Unpublished or retrospective studies were not considered eli-
gible. Levels of evidence were not used to assess the value of
each publication selected for inclusion. The following criteria
for inclusion were applied: (a) The study aimed to prospec-
tively evaluate the efficacy of two or more antiemetic strate-
gies in the prevention of delayed CINV after the administra-
tion of moderately emetogenic chemotherapy not containing
anthracyclines and cyclophosphamide (non-ACMEC). (b) At
least one of the following endpoints was used in the study: (1)
complete response, (2) complete control, (3) no nausea, (4) no
vomiting, or (5) no use of rescue medication. Studies on pa-
tients receiving chemotherapy with mixed emetogenicity
(HEC and/or AC and/or non-AC MEC) were included only
if subgroup analysis (pre-planned or ad hoc) of the non-AC
MEC subgroup was performed. When data on AC and non-
ACMEC were combined, it was arbitrarily decided to include
studies in which the percentage of patients receiving AC was
less than 50 % in the subgroup analysis. Both RCTs in which
the antiemetic therapies only differed beyond day 1, and RCTs
in which there was a difference starting at day 1 were
included.
Data extraction
Extracted items were study design, number of patients includ-
ed, number of patients receiving non-AC MEC, tumor types,
emetogenic level of assessed chemotherapeutic agents, prima-
ry efficacy endpoints, intervention, and reported results. Be-
cause of the heterogeneity in study designs, risk of bias, and
variety in patient populations, conducting a meta-analysis was
not possible.
Results
Number of studies meeting selection criteria
Using the PubMed syntax and aforementioned limits,
247 potentially relevant studies were identified.
Figure S1 (available at the Journal of Supportive Care
in Cancer online) depicts the subsequent stepwise selec-
tion of nine eligible studies. Searching conference pro-
ceedings of ASCO, ESMO, and MASCC did not pro-
vide additional eligible studies.
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Characteristics eligible studies
Our search provided nine studies which met the selection
criteria [18–26]. Mean sample size was 320 patients. Mean
number of patients receiving non-AC MEC was 230. All but
three studies assess patients with various tumor types. Most
studies assessed antiemetics in patients receiving a broad
range of chemotherapy regimens, including HEC, AC, and
MEC regimens; three studies assessed non-AC MEC only.
Most studies were double-blinded, including one phase II tri-
al. Three had a crossover study design. Two were non-
inferiority trials. Palonosetron was assessed in three studies,
including one evaluating a dexamethasone-sparing regimen.
NK1 receptor antagonists were assessed in three studies, in-
cluding one evaluating casopitant. Although casopitant was
discontinued for further development, we included data from
this RCT because they provide evidence to clarify the usage of
NK1 receptor antagonists for non-ACMEC. Other antiemetics
assessed were netupitant/palonosetron (NEPA), olanzapine,
and megestrol acetate, each in one study. CR (defined as Bno
vomiting,^ and/or Bno use of rescue antiemetics^) in the acute,
delayed, and overall phases was the primary efficacy endpoint
in the majority of the studies included. Study details are sum-
marized in Table 1.
Palonosetron
An open-label, crossover trial was designed to evaluate the
efficacy of palonosetron compared with ondansetron [19].
This study included 30 patients with head and neck cancer.
All patients received the same non-AC MEC regimen doce-
taxel 60 mg/m2, carboplatin 300 mg/m2, and 5-fluorouracil
600 mg/m2. Previous exposure to chemotherapy is unknown.
Corticosteroids were administered to all patients on day 1. CR
(defined as no vomiting) and intensity of nausea in the acute,
delayed, and overall phases were the primary efficacy end-
points in this study. There were no significant differences in
CR rates in all phases (palonosetron vs. ondansetron: acute
phase 83.3 vs. 80 %; delayed phase 76.6 vs. 66.7 %; overall
phase 66.7 vs. 46.7 %; p values not provided). Differences in
control of nausea were also not statistically significant during
all phases.
In a multicenter, double-blind, non-inferiority, crossover
trial, 144 patients with a broad range of tumor types receiving
HEC (cisplatin), AC, or non-AC MEC were randomized to
palonosetron in cycle 1, and then switched to granisetron in
cycle 2 or vice versa [20]. Both chemotherapy naïve and non-
naïve patients were included. Corticosteroids were not
allowed. The primary efficacy endpoint in this study was the
proportion of patients with CR (no vomiting) during the acute,
delayed, and overall phases. One hundred and eight patients
(75 %) received AC or non-ACMEC (63 % of patients in this
subgroup). One hundred and twenty-two patients received
two cycles of chemotherapy. Data of both cycles were pooled.
In the mixed AC/non-AC subgroup, differences in CR rates
between palonosetron and granisetron were not significant; in
the acute phase 72.16 vs. 67.65 %; in the delayed phase 67.01
vs. 59.80 %; in the overall phase 58.76 vs. 52.9 %, respective-
ly. p values not provided.
Dexamethasone-reducing study
A multicenter, open-label, non-inferiority study published in
2011 was designed to evaluate the efficacy of palonosetron
plus single-day dexamethasone compared with multiday
dexamethasone. This study included 332 patients receiving
AC or non-AC MEC, mainly oxaliplatin-, irinotecan-, and
carboplatin-based regimens [18]. All patients were chemo-
therapy naïve. CR (defined as no vomiting, no use of rescue
medication) during the overall phase was the primary outcome
measure. In the overall population, differences in CR rates
during the overall phase were significant (67.5 % for single-
day dexamethasone and 71.1 % for dexamethasone on days
1–3; difference, 95 % CI −3.6 % (−13.5 to 6.3)). In the non-
AC MEC subgroup analysis, there were no significant differ-
ences in CR rates between the single-day and multiday dexa-
methasone groups (in the acute phase, 88.3 vs. 87.0%, respec-
tively (difference, 95 % CI 1.3 (−7.6 to 10.2)); in the delayed
phase, 71.2 vs. 76.0 %, respectively (difference, 95 % CI −4.8
(−16.7 to 7))).
NK1 receptor antagonists
In a multicenter, double-blind study by Rapoport et al., 848
patients receiving AC and non-AC MEC for a broad range of
tumors were randomized to compare the efficacy of an oral
three-drug regimen of aprepitant, ondansetron, and dexameth-
asone to an oral control regimen of ondansetron and dexa-
methasone [21]. Fifty-two percent of the patients were given
non-AC-based MEC, including oxaliplatin, carboplatin,
ifosfamide, and irinotecan. All patients were chemotherapy
naïve. The primary efficacy endpoint of the study was the
proportion of patients reporting no vomiting during the overall
phase. In the overall population, a significantly higher propor-
tion of patients on aprepitant reported no vomiting in the over-
all phase compared to the control group (76.2 vs. 62.1 %,
respectively, p<0.001). In the post hoc analysis of the non-
AC MEC subgroup, statistically more patients in the
aprepitant group compared to the control group reported no
vomiting; in the acute phase, 96.5 vs. 91.6 %, respectively,
p<0.05; in the delayed phase, 84.5 vs. 73.9 %, respectively,
p<0.05; in the overall phase, 83.2 vs. 71.3 %, respectively,
p<0.05.
In a double-blind, parallel group study by Hesketh et al.,
enrolling 707 patients receiving non-AC MEC (oxaliplatin)
for colorectal cancer, the efficacy of single-dose casopitant
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was compared to placebo. All patients received ondansetron
on days 1–3 plus dexamethasone on day 1 and were chemo-
therapy naïve [22]. The primary endpoint in this study was the
percentage of patients achieving CR (defined as no vomiting,
no use of rescue medication) during the overall phase. There
were no significant differences between both groups; 86 % of
the patients in the casopitant group vs. 85 % in the placebo
group achieved CR (p=0.7273). There were also no signifi-
cant differences between the casopitant and placebo group in
the acute phase (97 vs. 96 %, respectively, p=0.4771) and in
the delayed phase (86 vs. 85 %, respectively, p=0.7273).
There was also no significant difference in severity of nausea
observed between casopitant and placebo in all phases.
Ninety-one female patients who were younger than
70 years, and received carboplatin-based chemotherapy for
gynecological tumors, were randomized to aprepitant or pla-
cebo in a multicenter, double-blind, phase II trial [23]. All
patients received granisetron and multiday corticosteroids.
Previous exposure to chemotherapy is unknown. The primary
endpoint in the study was CR (no vomiting, no rescue medi-
cation) during the overall phase. CR rates were not significant-
ly different between aprepitant and placebo in the overall
phase (62 vs. 52 %, respectively, p=0.33). There were also
no significant differences in CR rates during the acute and
delayed phases between aprepitant and placebo (98 vs.
96 %, respectively, and 62 vs. 52 %, respectively).
NEPA, a fixed-dose combination of netupitant
and palonosetron
In a multicenter, double-blind study by Gralla et al., the effi-
cacy of a single dose of NEPA (oral fixed-dose combination of
300 mg netupitant and 0.50 mg palonosetron) was compared
to oral aprepitant plus oral palonosetron 0.50 mg, in 412 pa-
tients treated with either HEC or non-ACMEC regimens for a
broad range of tumors [24]. Seventy-six percent of the patients
received non-AC MEC, mainly carboplatin- and oxaliplatin-
based chemotherapy. In this study, the dose/schedule of oral
dexamethasone was open label and based on the
emetogenicity of the chemotherapeutic regimen. All patients
were chemotherapy naïve. The study was not only designed
primarily to assess the safety of NEPA, but also assessed the
efficacy of this antiemetic drug. Overall incidence, type, and
frequency of adverse events were comparable between the
treatment groups. In the overall population, CR rates (no
vomiting, no use of rescue medication) in the overall phase
were similar in cycle 1 (81 % in the NEPA group vs. 76 % in
the control arm). The reported control of nausea was compa-
rable in both groups: 84–92 % across cycles for NEPA and
81–87 % for the control group. For the non-AC MEC sub-
group, CR rates across cycles were also comparable between
the treatment groups: 80–93 % in the NEPA group and 82–
89 % in the control group.
Olanzapine
In 229 patients with a broad range of tumors, the efficacy of
olanzapine was compared to the 5-HT3 receptor antagonist
azasetron in an open-label trial by Tan et al. [25]. Patients
receiving HEC, AC, or non-AC MEC were randomized to
olanzapine 10 mg days 1–5 plus azasetron 10 mg i.v. and
dexamethasone 10 mg i.v. on day 1, or to the control group
with azasetron 10 mg i.v. on day 1 plus dexamethasone 10 mg
i.v. days 1–5. Both chemotherapy-naïve and non-naïve pa-
tients were included. Fifty-six percent of all randomized pa-
tients received AC or non-AC MEC. In this mixed subgroup,
55 % of the patients received non-AC MEC, mainly
oxaliplatin-based chemotherapy. The primary endpoint in this
study was CR (no nausea and vomiting, no use of rescue
medication) during the acute, delayed, and overall phases. In
the overall population, CR rates in the acute phase were very
high (>95 %) and did not significantly differ between
olanzapine and 5-day dexamethasone in both the HEC and
combined AC and non-ACMEC subgroups. In the combined
subgroup, CR rates in the delayed phase were 83 % for the
olanzapine group vs. 58 % for the control group (p<0.05); in
the overall phase, 83 and 56 %, respectively (p<0.05).
Megestrol acetate
One hundred patients with gastrointestinal or lung cancer,
who were treated with HEC or non-AC MEC (mainly
oxaliplatin- and irinotecan-based chemotherapy), were ran-
domized in a single-blind, crossover trial published in 2011,
to receive either oral megestrol acetate 320 mg or placebo
[26]. Corticosteroids were not allowed in this study. Informa-
tion on previous treatment with chemotherapy was not pro-
vided. CR rates in the acute, delayed, and overall phases were
primary endpoints. In the non-ACMEC subgroup (44% of all
patients), CR rates were significantly higher in the megestrol
acetate group: in the overall phase, 50 vs. 27.3 %, respectively
(p=0.002); in the acute phase, 72.7 vs. 59.1 %, respectively
(p=0.146); and in the delayed phase, 52.3 vs. 25.0 % (p=
0.000), respectively.
Discussion
This review focuses on recent RCTs assessing prophylactic
antiemetic treatment for delayed CINV following non-AC
MEC. Results from the included trials show a diversity of
antiemetic agents assessed. Because of heterogeneity in cho-
sen endpoints, including populations, chemotherapy regi-
mens, and tumor types, comparison of data from these studies
is limited. There are, however, several findings of interest. We
identified two trials comparing the efficacy of palonosetron to
first-generation 5-HT3 receptor antagonists. Both studies
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suggest that palonosetron is equally effective as first-
generation 5-HT3 receptor antagonists for the prevention of
acute and delayed CINVafter non-AC MEC. This conclusion
is consistent with results from recently performed study by
Roscoe et al. [27]. They found that in patients treated with
chemotherapy with mixed emetogenicity, including non-AC
MEC, palonosetron was not more effective than granisetron in
rates of average delayed nausea, which was the primary end-
point in this study, when both were combined with single-day
dexamethasone and the dopamine (D2) receptor antagonist
prochlorperazine. Because no non-AC MEC subgroup analy-
sis was performed, this study did not meet selection criteria for
inclusion in our review. On the other hand, the conclusions of
both studies included in our review are at variance with results
from a recently performed systematic review and meta-
analysis by Popovic et al. that showed that palonosetron was
superior to first-generation 5-HT3 receptor antagonists in
preventing acute and delayed CINV [28]. Data from AC and
non-AC MEC subgroups were pooled; therefore, this meta-
analysis does not specifically address the efficacy of
palonosetron for delayed CINV prophylaxis following non-
AC MEC.
Obviously, the two included studies regarding
palonosetron have some limitations. Both have a crossover
design, which causes a considerable risk of bias, including
the possibility of a Bcarry over^ of treatment effect from one
chemotherapy cycle to the next. The investigators have min-
imized this risk by pooling data from cycles 1 and 2. More-
over, the total number of included patients on non-AC MEC
regimenswas only 138. Also, multiday dexamethasone for the
prevention of delayed CINV was not allowed in both trials,
which is not consistent with current guideline recommenda-
tions. This could have influenced the outcome measures used
in these studies. Furthermore, CR in the delayed phase was not
a primary but secondary endpoint in the largest study. It is
doubtful whether this trial was powered sufficiently to detect
a difference in both endpoints. Considering this, we conclude
that at present, there is still insufficient data to decide whether
palonosetron is the preferred 5-HT3 receptor antagonist fol-
lowing non-AC MEC.
As mentioned before, current guidelines recommend the
use of multiday dexamethasone to prevent delayed CINVafter
non-AC MEC. Dexamethasone use is often accompanied by
unpleasant side effects. Reduction of dexamethasone expo-
sure, without a decrease in efficacy, could be beneficial for
patients. One study we included in our review reported that the
efficacy of a single-day regimen of palonosetron and dexa-
methasone is non-inferior to palonosetron and multiday dexa-
methasone in the acute, delayed, and overall phases following
non-AC MEC. This evidence may be of particular benefit to
patients undergoing multiple cycles of therapy when
palonosetron is prescribed and where the long-term side ef-
fects of dexamethasone can be reduced.
While the major guidelines do not recommend the use of an
NK1 receptor antagonist for non-AC MEC, there is some ev-
idence that adding aprepitant may improve control of
vomiting. Results from the study by Rapoport et al. show that
a significantly higher proportion of patients on aprepitant re-
ported the primary outcome of no vomiting during all phases.
This study, however, has some limitations. For example, non-
ACMEC subgroup analysis was not predefined. Furthermore,
multiday ondansetron was used as an active control arm for
delayed CINV prophylaxis, which is not justified anymore by
clinical evidence [29]. Data from two other included studies
assessing NK1 receptor antagonists are in contrast with the
study by Rapoport et al. Both studies were well-designed
and assessed the additional effect of NK1 receptor antagonists
to first-generation 5-HT3 receptor antagonists in homoge-
neous patient populations with clearly defined tumor types,
treated with oxaliplatin- or carboplatin-based chemotherapy.
Adding NK1 receptor antagonists did not improve CR rates
during the acute and delayed phase. Therefore, we conclude
that so far no convincing evidence exists indicating benefits
from adding NK1 receptor antagonists to standard prophylac-
tic antiemetic treatment following non-AC MEC.
Some phase II studies suggested that adding a NK1 recep-
tor antagonist to palonosetron and dexamethasone causes high
CR rates in patients undergoing HEC or non-AC MEC [30,
31]. CR rates of more than 95 and 85 % could be achieved
during the acute and delayed phase, respectively, for patients
treated with carboplatin-based chemotherapy. This led to the
drug development of NEPA, an oral fixed-dose combination
of netupitant, which is a highly selective NK1 receptor antag-
onist, and palonosetron.We included the study byGralla et al.,
which concluded that this combination drug was safe, well
tolerated, and highly effective, when compared to oral 3-day
aprepitant and palonosetron, and when both treatment groups
are combined with dexamethasone [24]. Because this study
was designed primarily to assess the safety of NEPA, we be-
lieve that future RCTs should be performed to investigate the
efficacy of NEPA in clearly predefined AC and non-ACMEC
subgroups.
New anti-CINV regimens for non-AC MEC are evolving.
Recently, it was noticed that olanzapine, an atypical antipsy-
chotic, combined with a single dose of dexamethasone and
palonosetron was highly effective at controlling acute and
delayed CINVin patients receiving HEC [32]. Tan et al. found
highly significant CR rates for delayed CINV prophylaxis
following non-AC MEC with multiday olanzapine compared
to multiday dexamethasone [25]. Consequently, olanzapine
could combine reduction of dexamethasone exposure with
improved efficacy. This study has some limitations, however,
like its open-label design, which could have influenced out-
come measures. Moreover, AC and non-AC regimens were
taken together in the subgroup analysis. Future studies in
clearly defined non-AC MEC subgroups should assess
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whether the use of olanzapine results in better CR rates for
delayed CINVafter non-AC MEC.
The antiemetic potential of megestrol acetate was assessed
in one trial in a small population, receiving chemotherapywith
mixed emetogenicity [26]. The authors reported highly signif-
icant CR rates for non-AC MEC-treated patients, when
megestrol acetate was compared to placebo. All patients re-
ceived granisetron and metoclopramide, but corticosteroids
were not allowed. Subgroup analysis for MEC contained both
AC and non-AC regimens, which could influence the results.
Megestrol acetate should be compared in future trials with
standard antiemetics.
There are some limitations of this review. Data of the in-
cluded RCTs could not be synthesized because of the hetero-
geneity of antiemetic regimens, patient populations, and var-
iance of primary outcomes. AC and non-ACMEC were often
combined in subgroup analyses, making it hard to draw firm
conclusions for non-AC MEC regimens.
We conclude that high-level evidence for optimal prophy-
laxis of delayed CINV after non-AC MEC is lacking. We
believe that further research is essential to improve antiemetic
treatment efficacy and outcome while treatment (dexametha-
sone)-related toxicities are minimized and acceptable.
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